The dairy giant is backing its patented strain with a documentary, and a Peking University professor links it to a metabolite tied to GLP-1 release.
Recap by typeshit. Full story at FoodNavigator.com.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
Citing the Wall Street Journal, Daily Mail Australia says personal injury firm Weitz and Luxenberg brought nearly all of the claims against the Wegovy and Ozempic maker.
The Wall Street Journal reports the personal-injury firm has brought close to 100 suits since 2025. Plaintiffs say they developed the eye condition NAION while on Wegovy or Ozempic.
Loading…